deltatrials
Unknown PHASE3 INTERVENTIONAL 2-arm NCT04416035

A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC (NSCLC)

A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in Subjects With Advanced Nonsquamous NSCLC

Sponsor: Zhejiang Teruisi Pharmaceutical Inc.

Conditions Advanced Non-squamous Non-small-cell Lung Cancer
Interventions Carboplatin China-approved Bevacizumab Paclitaxel TRS003
Updated 6 times since 2020 Last updated: Aug 27, 2020 Started: Aug 17, 2020 Primary completion: Oct 21, 2021 Completion: Nov 10, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04416035, this PHASE3 trial focuses on Advanced Non-squamous Non-small-cell Lung Cancer and remains ongoing. Sponsored by Zhejiang Teruisi Pharmaceutical Inc., it has been updated 6 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Nov 2022 · 22 months · monthly snapshotRecruiting~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  3. Nov 2022 — Jul 2024 [monthly]

    Unknown Status PHASE3

    Status: Recruiting → Unknown Status

  4. Jan 2021 — Nov 2022 [monthly]

    Recruiting PHASE3

  5. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

  1. Jul 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Zhejiang Teruisi Pharmaceutical Inc.
Data source: Zhejiang Teruisi Pharmaceutical Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations